Evidence map›Paper›PMID 33129304›Full record

Trial reportBMC cancer2020

Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide.

Nikki McCaffrey, Tegan Asser, Belinda Fazekas, Wendy Muircroft, Meera Agar, Katherine Clark, Simon Eckermann, Jessica Lee, Rohit Joshi, Peter Allcroft and 2 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  4. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Guideline
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Nikki McCaffreyDeakin Health Economics, Centre for Population Health Research, School of Health and Social Development, Deakin University, Geelong, Victoria, Australia. nikki.mccaffrey@deakin.edu.au.ORCID http://orcid.org/0000-0003-3684-3723
Tegan AsserSchool of Medicine, Flinders University, Bedford Park, South Australia, Australia.
Belinda FazekasIMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.
Wendy MuircroftSouthern Adelaide Palliative Services, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia.
Meera AgarIMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.
Katherine ClarkCancer & Palliative Care Network, Northern Sydney Local Health District, St Leonards, New South Wales, Australia.
Simon EckermannCentre for Health Service Development, Australian Health Services Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.
Jessica LeeIMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.
Rohit JoshiMedical Oncology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.
Peter AllcroftSouthern Adelaide Palliative Services, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia.
Caitlin SheehanCalvary Heath Care, Kogarah, New South Wales, Australia.
David C CurrowIMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.
University of Technology Sydney · AUWomen's and Children's Health Network · AUCalvary Hospital · AUDeakin University · AUFlinders University · AULyell McEwin Hospital · AUThe University of Sydney · AUUniversity of Wollongong · AU

Funding

Department of Health, Australian Government N/A
6 · The paper itself

Abstract

backgroundThis analysis aims to evaluate health-related quality of life (HrQoL) (primary outcome for this analysis), nausea and vomiting, and pain in patients with inoperable malignant bowel obstruction (IMBO) due to cancer or its treatments randomised to standardised therapies plus octreotide or placebo over a maximum of 72 h in a double-blind clinical trial.

methodsAdults with IMBO and vomiting recruited through 12 services spanning inpatient, consultative and community settings in Australia were randomised to subcutaneous octreotide infusion or saline. HrQoL was measured at baseline and treatment cessation (EORTC QLQ-C15-PAL). Mean within-group paired differences between baseline and post-treatment scores were analysed using Wilcoxon Signed Rank test and between group differences estimated using linear mixed models, adjusted for baseline score, sex, age, time, and study arm.

resultsOne hundred six of the 112 randomised participants were included in the analysis (n = 52 octreotide, n = 54 placebo); 6 participants were excluded due to major protocol violations. Mean baseline HrQoL scores were low (octreotide 22.1, 95% CI 14.3, 29.9; placebo 31.5, 95% CI 22.3, 40.7). There was no statistically significant within-group improvement in the mean HrQoL scores in the octreotide (p = 0.21) or placebo groups (p = 0.78), although both groups reported reductions in mean nausea and vomiting (octreotide p < 0.01; placebo p = 0.02) and pain scores (octreotide p < 0.01; placebo p = 0.03). Although no statistically significant difference in changes in HrQoL scores between octreotide and placebo were seen, an adequately powered study is required to fully assess any differences in HrQoL scores.

conclusionThe HrQoL of patients with IMBO and vomiting is poor. Further research to formally evaluate the effects of standard therapies for IMBO is therefore warranted.

trial registrationAustralian New Zealand Clinical Trials Registry ACTRN12608000211369 (date registered 18/04/2008).

Indexed as

Quality of LifeAgedAntineoplastic Agents, HormonalCase-Control StudiesDouble-Blind MethodFemaleFollow-Up StudiesHumansIntestinal ObstructionMaleMiddle AgedNeoplasmsOctreotidePrognosisProspective StudiesAntineoplastic Agents, HormonalOctreotideIntestinal obstructionNeoplasmsPalliative carePatient-reported outcome measuresRandomised controlled trialsTerminal care

Identifiers

PMID33129304
PMCPMC7603764
OpenAlexW3097247236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.